Clinical Trial Update: Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) [Phase 4]

View source ↗

Summary

A Phase 4 study investigating whether growth factor concentrations can predict response to infliximab in ankylosing spondylitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Spondylitis, Ankylosing | Phase 4 | Status: COMPLETED